Formerly Kabra Drugs, Aanjaay Industries has posted a standalone profit of Rs 4.96 crore for FY26, marking a major turnaround. The company has shifted focus from stagnant pharmaceutical formulations to diversified wholesale and industrial trading. While revenue jumped to Rs 92.74 crore, the company faces significant liquidity pressure, with trade receivables ballooning to Rs 70.78 crore, raising concerns regarding cash flow quality despite accounting gains.
Aanjaay Industries Reports FY26 Profit Following Strategic Pivot
Revenue for FY26 reached Rs 92.74 crore, with a Profit After Tax of Rs 4.96 crore.
Reader Takeaway: Revenue growth signals a successful turnaround, but ballooning trade receivables pose a significant liquidity risk.
What just happened
Kabra Drugs Limited has officially transformed into Aanjaay Industries Limited, following a pivot from pharmaceutical formulations to wholesale and industrial trading. The company reported a significant financial turnaround for the fiscal year ended 31 March 2026, shifting from a loss of Rs 1.09 crore in the previous year to a profit of Rs 4.96 crore. This change included a relocation of the corporate office to Chennai and a major reshuffle of the Board of Directors.
Why this matters
The company’s revenue surge to Rs 92.74 crore validates the shift in business model. However, the quality of these earnings is under scrutiny. Despite the profit, operating cash flow remains negative at Rs 9.46 crore, driven primarily by a massive accumulation of trade receivables, which now account for 82% of the company's total assets.
Governance and Board Changes
The transition period saw extensive management changes. Key departures include former CFO Bangalore Venkatakrishnappa Ananth Kumar and several independent directors. New leadership appointments, including CFO Mr. Pavanasam and a revised board of independent directors, are now overseeing the scaled-up industrial supply operations.
Risks to watch
Investors must watch the working capital cycle closely. The sharp rise in trade receivables to Rs 70.78 crore suggests potential delays in payment collections, which can impact liquidity. Additionally, trade payables have risen to Rs 54.88 crore, highlighting a reliance on credit-based operations. The ability of the management to normalize cash flow and convert accounting profits into actual liquidity will be the primary measure of the company’s stability in the coming year.
What to track next
Watch for subsequent quarterly filings to see if trade receivables are brought under control and if the company can demonstrate sustainable, positive operating cash flow.